Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

Is There Still a Role for Triple Therapy Based on Recent Studies?

Presenter: Walter Desmet, Guy J. Friedrich

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

News Conference News ESC 2018

FFRCT Shifts Patient Management, Linked to Better 90-Day Outcomes: ADVANCE Registry

Caitlin E. Cox

September 07, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

News Daily News

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

Caitlin E. Cox

June 11, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

Advertisement

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Is There Still a Role for Triple Therapy Based on Recent Studies?

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

FFRCT Shifts Patient Management, Linked to Better 90-Day Outcomes: ADVANCE Registry

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

New Review Probes Possibility of CVD Prevention Without Aspirin

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

TCTMD’s Top 10 Most Popular Stories for April 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content